68Ga-PSMA PET/CT、18F-氟化钠 PET/CT 与弥散加权 MRI 在前列腺癌生化复发患者骨转移检测中的前瞻性比较
这项前瞻性研究纳入68例生化复发前列腺癌患者,比较68Ga-PSMA PET/CT、18F-NaF PET/CT与弥散加权MRI(DW600-MRI)检测骨转移的诊断准确性。68例中10例诊断为骨转移。68Ga-PSMA PET/CT与18F-NaF PET/CT诊断准确性相当且均较高,两者均显著优于DW600-MRI,后者按欧洲泌尿生殖放射学会指南施行时不足以诊断骨转移。
要点
- 68例生化复发前列腺癌患者中10例诊断为骨转移。
- 68Ga-PSMA PET/CT与18F-NaF PET/CT诊断骨转移准确性相当且均较高。
- DW600-MRI诊断准确性显著低于上述两种PET/CT,不足以诊断骨转移。
核心结论
- 68Ga-PSMA PET/CT与18F-NaF PET/CT在生化复发前列腺癌患者中检测骨转移显示出相当且较高的诊断准确性。
- 两者诊断性能均显著优于DW600-MRI,后者按欧洲泌尿生殖放射学会指南施行时不足以诊断骨转移。
研究设计与样本
- 前瞻性研究纳入68例生化复发前列腺癌患者,均行68Ga-PSMA PET/CT、18F-NaF PET/CT及按欧洲泌尿生殖放射学会指南施行的DW600-MRI(b值0和600 s/mm2)。
- 由至少两名有经验观察者用三点量表(良性、恶性或可疑转移)和二分量表(良性或转移)对骨病灶分类。
- 以研究特定影像、至少12个月临床随访及研究前和研究期间任何影像定义最佳参考标准。
- 诊断性能采用敏感性分析评估,可疑病灶分别按非转移和转移处理。
主要发现
- 68例中10例诊断为骨转移。
- 患者水平68Ga-PSMA PET/CT(n=68例)敏感性0.80、特异性0.98-1.00、AUC 0.89-0.90。
- 患者水平18F-NaF PET/CT(n=67例)敏感性0.90、特异性0.90-0.98、AUC 0.90-0.94。
- 患者水平DW600-MRI(n=60例)敏感性0.25-0.38、特异性0.87-0.92、AUC 0.59-0.62。
- DW600-MRI诊断骨转移性能显著低于68Ga-PSMA PET/CT和18F-NaF PET/CT(p<0.01);68Ga-PSMA PET/CT与18F-NaF PET/CT的AUC无显著差异(p=0.65)。
关键数值与推荐
- 骨病灶分类采用三点量表(良性、恶性或可疑转移)和二分量表(良性或转移)。
- DW600-MRI按欧洲泌尿生殖放射学会指南施行,b值为0和600 s/mm2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively compare diagnostic accuracies for detection of bone metastases by 68Ga-PSMA PET/CT, 18F-NaF PET/CT and diffusion-weighted MRI (DW600-MRI) in prostate cancer (PCa) patients with biochemical recurrence (BCR). METHODS: Sixty-eight PCa patients with BCR participated in this prospective study. The patients underwent 68Ga-PSMA PET/CT, a 18F-NaF PET/CT and a DW600-MRI (performed in accordance with European Society of Urogenital Radiology guidelines, with b values of 0 and 600 s/mm2). Bone lesions were categorized using a three-point scale (benign, malignant or equivocal for metastases) and a dichotomous scale (benign or metastatic) for each imaging modality by at least two experienced observers. A best valuable comparator was defined for each patient based on study-specific imaging, at least 12 months of clinical follow-up and any imaging prior to the study and during follow-up. Diagnostic performance was assessed using a sensitivity analysis where equivocal lesions were handled as non-metastatic and then as metastatic. RESULTS: Ten of the 68 patients were diagnosed with bone metastases. On a patient level, sensitivity, specificity and the area under the curve (AUC) by receiver operating characteristic analysis were, respectively, 0.80, 0.98-1.00 and 0.89-0.90 for 68Ga-PSMA PET/CT (n = 68 patients); 0.90, 0.90-0.98 and 0.90-0.94 for 18NaF PET/CT (n = 67 patients); and 0.25-0.38, 0.87-0.92 and 0.59-0.62 for DW600-MRI (n = 60 patients). The diagnostic performance of DW600-MRI was significantly lower than that of 68Ga-PSMA PET/CT and 18NaF PET/CT for diagnosing bone metastases (p < 0.01), and no significant difference in the AUC was seen between 68Ga-PSMA PET/CT and 18NaF PET/CT (p = 0.65). CONCLUSION: 68Ga-PSMA PET/CT and 18F-NaF PET/CT showed comparable and high diagnostic accuracies for detecting bone metastases in PCa patients with BCR. Both methods performed significantly better than DW600-MRI, which was inadequate for diagnosing bone metastases when conducted in accordance with European Society of Urogenital Radiology guidelines.
引用
- Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29876619. doi:10.1007/s00259-018-4058-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。